Søren Echwald has been named CEO at Anapa Biotech. The Danish biotech, previously called QuantiBact, is developing molecular tools to enhance the performance of natural nucleic acids in PCR and hybridization-based assays.
Echwald joins Anapa from Exiqon, where he was vice president of business development. He takes over the CEO position from Palle Schelde, who has left the company to pursue other opportunities in the biotech industry, Anapa said.